I Y Cheung
Overview
Explore the profile of I Y Cheung including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
323
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Beiske K, Burchill S, Cheung I, Hiyama E, Seeger R, Cohn S, et al.
Br J Cancer
. 2009 Apr;
100(10):1627-37.
PMID: 19401690
Disseminating disease is a predictive and prognostic indicator of poor outcome in children with neuroblastoma. Its accurate and sensitive assessment can facilitate optimal treatment decisions. The International Neuroblastoma Risk Group...
2.
Chi S, Cheung N, Cheung I
Int J Biol Markers
. 2003 Jan;
17(4):219-23.
PMID: 12521124
The SSX genes are members of the family of cancer/testis antigens that encode tumor-associated antigens recognizable by autologous cytolytic T lymphocytes. Their expression is common in tumors of diverse lineages...
3.
Lo Piccolo M, Cheung N, Cheung I
Cancer
. 2001 Sep;
92(4):924-31.
PMID: 11550167
Background: Neuroblastomas (NBs) almost ubiquitously express the ganglioside GD2. GD2 synthesis is dependent on the key enzyme GD2 synthase. Thus, GD2 synthase transcript may prove to be a potential molecular...
4.
Cheung N, Kushner B, LaQuaglia M, Kramer K, Gollamudi S, Heller G, et al.
Med Pediatr Oncol
. 2001 Jul;
36(1):227-30.
PMID: 11464891
Background: The N7 protocol for poor-risk neuroblastoma uses dose-intensive chemotherapy (as in N6 protocol [Kushner et al.: J Clin Oncol 12:2607-2613, 1994] but with lower dosing of vincristine) for induction,...
5.
Cheung I, Cheung N
Med Pediatr Oncol
. 2001 Jul;
36(1):210-2.
PMID: 11464887
Background: We first explored the use of multiple molecular markers to overcome tumor heterogeneity. Sixty-seven neuroblastoma (NB) tumors were tested for the expression of GAGE, MAGE-2, MAGE-2, MAGE-3, and MAGE-4...
6.
Cheung I, Cheung N
Clin Cancer Res
. 2001 Jun;
7(6):1698-705.
PMID: 11410509
Purpose: GD2 is abundantly expressed in neuroblastoma (NB). GD2 synthesis is dependent on key enzyme beta 1,4-N-acetylgalactosaminyltransferase (GD2 synthase). We explore the potential of GD2 synthase mRNA as a molecular...
7.
Cheung N, Guo H, Cheung I
Med Pediatr Oncol
. 2000 Dec;
35(6):635-7.
PMID: 11107135
Background: A transient human anti-mouse antibody response was associated with significantly longer survival [Cheung et al. (1998): J Clin Oncol 16:3053] following antibody 3F8 (Ab1) treatment. We postulate that the...
8.
Cheung I, Chi S, Cheung N
Med Pediatr Oncol
. 2000 Dec;
35(6):632-4.
PMID: 11107134
Background: Previously, we reported the utility of GAGE as a molecular marker for neuroblastoma (NB) and malignant melanoma in blood and bone marrow (BM). Among patients with stage III melanoma...
9.
Cheung N, Guo H, Heller G, Cheung I
Clin Cancer Res
. 2000 Jul;
6(7):2653-60.
PMID: 10914706
Treatment with anti-G(D2) monoclonal antibody 3F8 (Ab1) at the time of remission may prolong survival for children with stage 4 neuroblastoma. A transient human antimouse antibody (HAMA) response was associated...
10.
Cheung I, Cheung N, Ghossein R, Satagopan J, Bhattacharya S, Coit D
Clin Cancer Res
. 1999 Sep;
5(8):2042-7.
PMID: 10473084
We used GAGE as a molecular marker to identify melanoma cells with metastatic potential in the peripheral blood and the bone marrow. One hundred thirty-three patients with malignant melanoma (21...